Answers are grounded in this paper and cite their sources.
Clinical findings demonstrate IMNN-001 enhances immunotherapy in ovarian cancer, suggesting improved treatment options.
IMNN-001 gene therapy could add clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. IMNN-001 holds promise for synergistic combinations with immunotherapies requiring intrinsic immune activity.
No takes yet. Share an insight, caveat, or question.
Thaker et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: